Fijación de radioyodo en huesos maxilares simulando metástasis en pacientes con Carcinoma Diferenciado de Tiroides (CDT): False- Positive images in patients with Differentiated Thyroid Carcinoma. (DTC) / Uptake of 131-I in maxillary bones mimicking salivary glands

En estudios centellográficos con 131I (CCT) para seguimiento, postablación o tratamiento de pacientes portadores de carcinoma diferenciado de tiroides (CDT) se observan frecuentemente en tiempos precoces áreas de captación del radiotrazador en macizo facial. Estas áreas corresponden, generalmente, a glándulas salivares y extremo anterior de mucosa nasal y se mantienen durante las primeras 48 horas y no son observadas generalmente a las 72 horas. Pero con menor frecuencia se presentan otras que persisten durante varias semanas; estas áreas fueron consideradas como posibles retención en glándulas salivares, en tejido tiroideo ectópico en piso de boca, o proteínas yodas entre otras causas. En 1996 Valdivieso y col. (Cong. Arg. Biol. Med. Nuclear, Mar del Plata) y Gutiérrez y col. (SLAT, Chile) consideraron además de las mencionadas posibilidades, que la fijación se podría realizar en hueso maxilar en relación con procesos dentales y esta idea se vio favorecida por dos presentaciones sobre pocos casos que coincidían con la idea sobre el lugar de fijación del radioelemento con producción de imágenes falsas-positivas de enfermedad metastática. Con el propósito de determinar la frecuencia de observación de estas imágenes se procedió a la revisión de 636 CCT efectuados entre el 1 de enero de 2002 y el 31 de diciembre de 2007 en 502 pacientes. En el 31,5 % de los pacientes se observaron áreas activas en maxilares que persistían por varias semanas; la intensidad de concentración fue del 0,3 al 1,2 % de la actividad administrada. En 10 pacientes se efectuaron áreas de interés sobre las zonas activas que se controlaron durante 3 semanas, determinándose el T ½ efectivo registrándose valores promedio de 6,87 ± 0,94 días muy próximos al T ½ físico del 131I, indicando fuerte unión del compuesto radiactivo formado. La intensidad de concentración del radioyodo es variable dependiendo de la intensidad de la lesión dental, (caries, prótesis, pulpitis, granulomas periapicales) y en especial se incrementa en pacientes provenientes del interior que habitaban en zonas con aguas con contenido de flúor o arsénico. Seis pacientes tratados con actividades altas de radioyodo de entre 5,55 y 11,1 MBQ (150 a 300 mCi) mostraron lesiones actínicas en mucosa bucal y lingual. En 5 pacientes se efectuaron inmediatamente después del CCT con radioyodo, estudios panorámicos de Rx maxilar y de centellograma óseo coincidiendo las imágenes maxilares positivas de ambos estudios con las áreas positivas con radioyodo, confirmándose la localización de las mismas. En 13 pacientes que se sometieron a intensos tratamientos odontológicos, en estudios de CCT posteriores se apreció la disminución de intensidad de las imágenes o su desaparición. Ninguno de los pacientes presentó metástasis de CDA en las áreas activas maxilares. Estos hallazgos confirman la concentración del radioyodo en hueso maxilar en relación con alteraciones, dentales debiendo efectuarse investigaciones más profundas sobre la naturaleza de la molécula formada y los mecanismo de fijación de la misma. Deberá tenerse en cuenta el estado de salud dentario del pacientes antes de someterlo a tratamiento de metástasis o ablaciones, en especial cuando las actividades de radioyodo a utilizar sean mayores de 3,7 GBq (100 mCi) y aún indicar tratamiento de las lesiones dentales en forma previa.

In the whole body scans (WBS) with 131I in the follow-up or treatment of patients bearing DTC it is observed frequently fixation areas of the tracer apparently in relation with salivary glands. These areas generally belong to the salivary glands and are present during the first 48/72 hours, but others are kept during more than 3 weeks. These latter ones were considered as possible uptake in ectopic thyroid cells in the mouth floor, iodized proteins, retention of salivary glands and other assertions. Valdivieso et al (Cong. Arg. Biol. Med. Nuclear, 1996) and Gutiérrez et al (SLAT,Chile, 1997) considered that the fixation took place also in maxillary bones probably in areas in relation with dental illness (inflammation, pulpitis, dental caries, perionditis, periapical granuloma, periapical cyst and resorption of surrounding bone seen radiologically as periapical radiolucency). This presumption was sustained for two publications (Clin. Nucl. Med. 1998;23. 747-749, and Clin. Nucl. Med. 2000; 23; 314-315). This end the review of 638 131I WBS carried out between January 1st, 2002 and December 31st of 2007 in 502 patients that were studied for ablation, treatment of metastasis or relapses or follow up. In 31,5% of the patients were observed areas of activity in maxilla. The intensity of concentration of the tracer was 0.3 to 1.2 % of the activity administered. In 10 patients was determinate the effective T ½ and in 5 a panoramic Rx of the maxilla and a bone scintigraphy with 99mTc-MDP; there were correlation between both images, the 131I one an the 99mTc-MDP with radiology. The effective T½ mean value was 6,87 days ± 0,94 (S.D.) very close to the physical T ½ of the radioiodine tracer indicating a strongly labeled molecule. In 6 patients treated with high activities of radioiodine (5,55 to 11,1 MBq - 150 to 300 mCi) actinic lesions were observed in mouth and lingual mucous membrane, including ulcers. The intensity of the images and of the lesions correlate with the intensity of the administered activity of radioiodine, the previous condition of dental integrity and in patients living in the interior of our country in zones of "bad" water containing tracers of arsenic and fluorine. In 13 patients submitted to intense treatment of dental problems posterior WBS showed a decrease of the positive maxilla areas or they were not found. The presence of metastasis in the active maxilla area was in all cases negative. Our observations confirm that radioiodine is deposited in maxillary bone in relation of dental lesions and that this 131I move in a very slow place. This mechanism of fixation has to be determined. We fully recommended taking into account the existence of dental illness or incomplete dental treatments when the administration of higher activities than 3.7 GBq (150 mCi).

Serum kinetics, bioavailability and bone scanning of 99mTc-labelled sodium olpadronate in patients with different rates of bone turnover.

The activity of olpadronate labelled with technetium-99m(99mTc) was monitored in plasma and urine samples after single oral (925 MBq 99mTc/10 mg, coadministered with 50 mg cold drug) and intravenous (925 MBq 99mTc/5 mg) administrations to two groups of patients with different rates of bone turnover. The first group comprised high bone turnover (HBTO) patients suffering from Paget's bone disease; the second group comprised patients with normal to low bone turnover (NBTO) having the diagnosis of rheumatoid arthritis and secondary osteoporosis. Kinetic variables were correlated with anthropomorphometric variables, biological markers of bone metabolism and plasma proteins. Data were also obtained after repeatedly dosing the HBTO patients. Additionally, Paget's bone and healthy bone (PB/HB) uptake before and after low-dose oral treatment were assessed by means of scintigraphy. Results showed that most of the kinetic variables did not differ between the two groups of patients, except for a greater Vss and smaller blood area under the curve AUC in the patients with HBTO. After a repeated-dose administration period, the blood AUC activity and Whole Body Retention (WBR) of the HBTO patients tended to be similar to those of the NBTO patients. In both groups, after oral dosing, the Cmax was 20 times lower than the C0.5 after i.v. injection, and the oral bioavailability ranged from 3% to 4%. Finally, the plasma t1/2 beta ranged from 9 to 14 h. Correlation coefficients were obtained from multiple regression analysis; kinetic variables showed very low correlations with anthropomorphometric measurements. In contrast the Vss and WBR were significantly correlated with serum alkaline phosphatase levels and the Vss also with urine hydroxyproline levels. Plasma protein concentration was also correlated with excretion parameters such as CLP and plasma t1/2 beta after an oral dose. Scintigraphic studies in the HBTO group allowed bone selectivity to be seen through skeletal drug uptake. The 15 Pagetic lesions analysed in the HBTO group showed a decrease in PB/HB ratio from 3.8 in the basal study to 2.7 after olpadronate administration for 30 days at the rate of 50 mg/day. In conclusion, the kinetic profile of 99mTc-labelled olpadronate, mainly AUC and WBR, showed a dependence upon bone metabolism and seemed unrelated to body size variables. HBTO patients showed a lower blood AUC but a higher Vss. Both variables may have been reflecting the fact that the drug binds selectively with calcified tissues and, in turn, with the target compartment. Scintigraphy confirmed the labelled-compound bone selectivity as a desirable feature for a bone-scanning agent.

[Serum thyroglobulin and whole-body scanning as markers in the follow-up of differentiated thyroid carcinomas]. / La tiroglobina sérica y el rastreo corporal total como indicadores en el seguimiento del carcinoma diferenciado de tiroides.

We have compared two "markers" in the follow up of post treatment (surgery and therapeutical use of I-131) differentiated thyroid carcinoma. In 153 patients, thyroglobulin (Tg) serum levels were measured after withdrawal of I-thyroxine therapy, before performing a whole-body scan (WBS) with iodine-131; in 55 of these patients, Tg was measured again after at least 45 days of I-thyroxine treatment. The patients were followed between 3 and 10 years, and there were 2713 matched studies. Our results indicate for both parameters, false positive and negative values; sensitivity (SE) for WBS was 89% and specificity (SP) 83%; Tg presents a SE of 86% and SP of 83%. Matching both parameters, SE was 95% and SP 98%. The causes of false results are discussed. Tg determinations under I-thyroxine treatment do not permit the establishment of absence of illness; 37.7% of patients with demonstrated metastases or relapse showed negative Tg values that reached pathological values after suspension of I-thyroxine treatment; another 41.4% with elevated Tg values under therapy reached these values after suspension of I-thyroxine. Both markers, when utilized at the same time, offer the best possibilities in the follow-up of differentiated thyroid carcinoma, when determinations are carried out after suspension of hormonal treatment.

La tiroglobulina sérica y el rastreo corporal total como indicadores en el seguimiento del carcinoma diferenciado de tiroides / Serum thyroglobulin and whole-body scan as markers in the follow up of differentiated thyroid carcinomas

Hemos comparado el valor de los indicadores en el seguimiento del carcinoma tiroideo diferenciado (CaDT): tiroglobulina sérica (Tg) y rastreo corporal total con I-131 (RCT), que fueron realizados entre 3 y 10 años después del tratamiento quirúrgico más dosis terapéutica de I-131. Se realizaron en 153 pacientes 2713 estudios apareados, que se efectuaron con suspensión de la opoterapia por más de 30 días. En 55 pac. se realizaron determinaciones de Tg bajo opoterapia y en 18 en las mismas condiciones, determinaciones seriadas durante 6 meses. Los resultados indican que ambos parámetros pueden presentar falsos positivos y negativos, discutiéndose las razones de los mismos. La sensibilidad (S) para RCT fue de 89% y la especificidad (E) de 83% y para Tg S de 86% y E de 83%; si se consideran ambos parámetros en forma conjunta, S 95% y E 98%. La determinación de Tg bajo opoterapia no permite estabelecer la existencia de metástasis o recidivas con iguales posibilidades que luego de suspensión de la misma. El 37,7% de los casos con enfermedad demostrable, presentaron valores negativos de Tg bajo opoterapia que se elevaron a valores patológicos ...

La tiroglobina sérica y el rastreo corporal total como indicadores en el seguimiento del carcinoma diferenciado de tiroides. / [Serum thyroglobulin and whole-body scanning as markers in the follow-up of differentiated thyroid carcinomas]

We have compared two [quot ]markers[quot ] in the follow up of post treatment (surgery and therapeutical use of I-131) differentiated thyroid carcinoma. In 153 patients, thyroglobulin (Tg) serum levels were measured after withdrawal of I-thyroxine therapy, before performing a whole-body scan (WBS) with iodine-131; in 55 of these patients, Tg was measured again after at least 45 days of I-thyroxine treatment. The patients were followed between 3 and 10 years, and there were 2713 matched studies. Our results indicate for both parameters, false positive and negative values; sensitivity (SE) for WBS was 89

and specificity (SP) 83

; Tg presents a SE of 86

and SP of 83

. Matching both parameters, SE was 95

and SP 98

. The causes of false results are discussed. Tg determinations under I-thyroxine treatment do not permit the establishment of absence of illness; 37.7

of patients with demonstrated metastases or relapse showed negative Tg values that reached pathological values after suspension of I-thyroxine treatment; another 41.4

with elevated Tg values under therapy reached these values after suspension of I-thyroxine. Both markers, when utilized at the same time, offer the best possibilities in the follow-up of differentiated thyroid carcinoma, when determinations are carried out after suspension of hormonal treatment.

La tiroglobulina sérica y el rastreo corporal total como indicadores en el seguimiento del carcinoma diferenciado de tiroides / Serum thyroglobulin and whole-body scan as markers in the follow up of differentiated thyroid carcinomas

Hemos comparado el valor de los indicadores en el seguimiento del carcinoma tiroideo diferenciado (CaDT): tiroglobulina sérica (Tg) y rastreo corporal total con I-131 (RCT), que fueron realizados entre 3 y 10 años después del tratamiento quirúrgico más dosis terapéutica de I-131. Se realizaron en 153 pacientes 2713 estudios apareados, que se efectuaron con suspensión de la opoterapia por más de 30 días. En 55 pac. se realizaron determinaciones de Tg bajo opoterapia y en 18 en las mismas condiciones, determinaciones seriadas durante 6 meses. Los resultados indican que ambos parámetros pueden presentar falsos positivos y negativos, discutiéndose las razones de los mismos. La sensibilidad (S) para RCT fue de 89% y la especificidad (E) de 83% y para Tg S de 86% y E de 83%; si se consideran ambos parámetros en forma conjunta, S 95% y E 98%. La determinación de Tg bajo opoterapia no permite estabelecer la existencia de metástasis o recidivas con iguales posibilidades que luego de suspensión de la misma. El 37,7% de los casos con enfermedad demostrable, presentaron valores negativos de Tg bajo opoterapia que se elevaron a valores patológicos ... (AU)

Technetium-99m APD compared with technetium-99m MDP as a bone scanning agent.

We have investigated the possibilities of technetium-99m-(-3-aminohydroxypropylidene)-1-1-bisphosphon ate ([99mTc]APD) as a bone scanning agent in 14 normal subjects and 28 patients. Similar studies in the same normal subjects and patients were carried out with 99mTc-methylene-bisphosphonate ([99mTc]MDP). The compounds were labeled with 99mTc by means of an electrolytical method; the free pertechnetate content was always under 1%. The [99mTc]APD T1/2 of the third component of the disappearance plasma curve in six normal subjects was 152 +/- 46 min (mean +/- s.d.), while the 24-hr whole-body retention (WBR) was 17.6% +/- 4.6. The [99mTc]MDP value of the 24-hr WBR was 28.6% +/- 3.9 (p less than 0.001). The bone/soft-tissue ratio (B/ST) was investigated in eight control subjects on the eleventh thoracic and the fourth lumbar vertebrae. The B/ST ratios were similar for both APD and MDP studies. In 28 patients with suspected bone metastasis or primary bone disease, bone scintigraphy was carried out; both compounds showed similar findings and the same number of positive results. In five of these patients, the lesion/normal bone ratio was determined with values of 4.6 +/- 2.0 in APD studies and 4.8 +/- 2.3 with MDP. APD was also used in 126 patients; no adverse reactions were observed. The APD dose used i.v. for bone scanning was 200-fold less than those employed by mouth per day, for the treatment of bone disease for long periods. In our experience, APD appears to be an adequate agent for bone scintigraphy.